A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : CCyR / complete cytogenetic response

[Related PubMed/MEDLINE]
Total Number of Papers: 229
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   CCyR  (>> Co-occurring Abbreviation)
Long Form:   complete cytogenetic response
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 Analysis of the Mortality of Russian Patients With Chronic Myeloid Leukemia in the Multicenter EUTOS ELN Population-based Study (EUTOS-PBS). AP, BC, CI, CML, CP, EUTOS-PBS, OS
2020 Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study. CML, CP, MCyR, MMR, TKIs
2020 Effects of Trough Concentration and Solute Carrier Polymorphisms on Imatinib Efficacy in Chinese Patients with Chronic Myeloid Leukemia. CML, CMR, MMR
2020 Feasibility Study of Switching to Nilotinib After First-line Imatinib in the Chronic Phase of Chronic Myeloid Leukemia. ELN, MMR, MR4.0
2020 Marrow fibrosis is an independent predictor of hematological toxicity of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. CML, MF, MMR, OS, PFS, TKIs
2020 Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia. ALL, CMR, CR, MMR, Ph-positive
2020 Real-world Experience of Imatinib in Pediatric Chronic Phase Chronic Myeloid Leukemia: A Single-center Experience From India. CHR, CML, EFS, TKIs
2020 Treatment outcomes of chronic-phase chronic myeloid leukemia with resistance and/or intolerance to a 1st-line tyrosine kinase inhibitor in Japan: the results of the New TARGET study 2nd-line. CML, CP, TKI
2020 Validation of the EUTOS Long-Term Survival Score in Chinese Chronic Myeloid Leukemia Patients Treated with Imatinib: A Multicenter Real-World Study. CML, ELTS, OS, PFS
10  2020 [Analysis of the efficacy and influencing factors of nilotinib or dasatinib as second- or third-line treatment in patients with chronic myeloid leukemia in the chronic phase and accelerated phase]. AP, CHR, CML, CP, MMR, OS, PFS, TKI
11  2019 Adolescent and Young Adult Chronic Myeloid Leukemia in Real-World Settings: Experience from a Tertiary Care Institute in Northern India. AYA-CML, MMR, OS
12  2019 Benefits and risks of ponatinib versus bosutinib following treatment failure of two prior tyrosine kinase inhibitors in patients with chronic phase chronic myeloid leukemia: a matching-adjusted indirect comparison. CP-CML, MAIC
13  2019 Clinical characteristics and prognostic significance of chronic myeloid leukemia with rare BCR-ABL1 transcripts. CML, TKI
14  2019 Comparative efficacy and tolerability of front-line treatments for newly diagnosed chronic-phase chronic myeloid leukemia: an update network meta-analysis. AEs, AP, CP-CML, MMR, SUCRA, TKIs
15  2019 FISH versus real-time quantitative PCR for monitoring of minimal residual disease in chronic myeloid leukaemia patients on tyrosine kinase inhibitor therapy. MMR, TKI, UKMMC
16  2019 Incidence of Clinically Significant (≤10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib. CML, CS, EFS, EPO
17  2019 Optimal Time Points for BCR-ABL1 Tyrosine Kinase Domain Mutation Analysis on the Basis of European LeukemiaNet Recommendations in Chronic Myeloid Leukemia. CHR
18  2019 Patched homolog 1 (PTCHI) gene mutations can predict the outcome of chronic myeloid leukemia patients? CML, Hh, PCR, PTCH1
19  2019 Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia. CML, CP, MMR, R/I
20  2019 Randomized study of imatinib for chronic myeloid leukemia: comparing standard dose escalation with aggressive escalation. ---
21  2019 Responses to Dasatinib as a Second- and Third-Line Tyrosine Kinase Inhibitor in Chronic Phase Chronic Myeloid Leukaemia Patients. BCR-ABL1IS, MMR
22  2019 Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients. CML, MMR
23  2019 [Analysis of clinical characteristics, treatment response rate and survival of 77 myelodysplastic syndrome patients with del (5q) syndrome]. ACA, CR, CyR, LEN, MDS, OS
24  2019 [Comparison of nilotinib vs imatinib as frontline therapy in newly diagnosed patients with chronic myeloid leukemia in chronic phase]. CML-CP, FFS, MMR, OS, PFS
25  2019 [Comparison of the efficacy and safety of Chinese generic imatinib and branded imatinib in patients with chronic myeloid leukemia in consideration of demographic characteristics]. CML-CP, FFS, MMR, OS, PFS
26  2019 [Efficacy and safety of domestic dasatinib as second-line treatment for chronic myeloid leukemia patients in the chronic phase]. AEs, CML-CP, EFS, MMR, PFS, TKI
27  2019 [Fertility and disease outcomes in patients with chronic myeloid leukemia]. CML, MMR, TKI
28  2019 [Prognosis of clonal chromosomal abnormalities in Philadelphia negative metaphases cells in chronic myeloid leukemia with tyrosine kinase inhibitor therapy]. CML, MMR, OS, TKI, UMRD
29  2018 Baseline BCR-ABL1 transcript type of e13a2 and large spleen size are predictors of poor long-term outcomes in chronic phase chronic myeloid leukemia patients who failed to achieve an early molecular response after 3 months of imatinib therapy. EMR, IM, MMR
30  2018 Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. CML, MMR
31  2018 Bosutinib: Valuable therapeutic option for the Bulgarian market. CML, TKIs
32  2018 Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience). AE, AP, CML, EFS, ELN, EUTOS, IM, MMR, MR4.5, OS, OS, PFS, TKI
33  2018 Clinical results according to age in patients with chronic myeloid leukemia receiving imatinib frontline: The younger, the later, the worse? CML, MMolR
34  2018 Comparative analyses of nilotinib versus high-dose imatinib versus sustained standard-dose imatinib in patients with chronic phase chronic myeloid leukemia following suboptimal molecular response to first-line imatinib. CML, IM, MMR, NIL
35  2018 Comparative efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukaemia: A systematic review and network meta-analysis. CML, MCyR, MMR, NMA, RCTs, SUCRA, TKIs
36  2018 Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial. CML-CP
37  2018 Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients. CML, DMR, MMR
38  2018 Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial. MMR, SCT
39  2018 Impact of SLC22A1 and CYP3A5 genotypes on imatinib response in chronic myeloid leukemia: A systematic review and meta-analysis. CML, MMR
40  2018 Megakaryocytes harbour the del(5q) abnormality despite complete clinical and cytogenetic remission induced by lenalidomide treatment. HSC
41  2018 Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. ACA, CML, MMR, TKIs
42  2018 Safety and efficacy of nilotinib in routine clinical practice in patients with chronic myeloid leukemia in chronic or accelerated phase with resistance or intolerance to imatinib: results from the NOVEL study. AEs, CML, MMR, OS, PFS, TKI
43  2018 Sudden blast phase in chronic myeloid leukemia developed during nilotinib therapy after major molecular response was achieved. CML, MMR, SBP
44  2018 The impact of early molecular response in children and adolescents with chronic myeloid leukemia treated with imatinib: a single-center study from China. CML, EFS, EMR, IM, IS, MMR
45  2018 The incidence of atypical patterns of BCR-ABL1 rearrangement and molecular-cytogenetic response to tyrosine kinase inhibitor therapy in newly diagnosed cases with chronic myeloid leukemia (CML). CML, MMR
46  2018 The significance of enzyme and transporter polymorphisms for imatinib plasma levels and achieving an optimal response in chronic myeloid leukemia patients. CML, MMR
47  2018 Therapeutic effects of tyrosine kinase inhibitors and subtypes of BCR-ABL1 transcripts in Japanese chronic myeloid leukemia patients with three-way chromosomal translocations. CML, MR, OS, PCyR, TKIs
48  2018 [Chronic myeloid leukemia presenting with marked eosinophilia]. CML
49  2018 [Comorbidity profile and its impact on reported outcome in Chinese patients with chronic myeloid leukemia in chronic phase receiving tyrosine kinase-inhibitor therapy]. CML-CP, HRQoL, ies, TKI
50  2018 [Effect of stopping tyrosine kinase inhibitors during pregnancy on disease status and reproductive outcomes among patients with chronic myeloid leukemia]. CML, CML-CP, CMR, MMR, TKI
51  2018 [Imatinib as Second-Line Treatment Drug for CML Patients Intolerant to Nilotinib]. MMR
52  2018 [Mean Corpuscular Volume Can Be A Predictor for Therapeutic Response of Patients with Chronic Myeloid Leukemia]. CML, CML-CP, MCV, TKI
53  2018 [The molecular-cytogenetic characterization and tyrosine kinase inhibitors efficacy in newly diagnosed chronic phase CML patients with variant Philadelphia chromosomes]. IM, MMR, TKIs, vPh
54  2017 A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia. CML, CML-CP, MMR
55  2017 Analysis of Survival of Patients with Chronic Myeloid Leukemia Treated with Imatinib in the Last 15 Years in Lebanon. CML, MMR, TKI
56  2017 Effects of Deeper Molecular Responses on Outcomes in Chronic Myeloid Leukemia Patients in Chronic Phase Treated With Imatinib Mesylate. CMR, MMR, PFS
57  2017 Exploratory study on the impact of switching to nilotinib in 18 patients with chronic myeloid leukemia in chronic phase with suboptimal response to imatinib. AEs, CML-CP, ENABL, IS, MMR
58  2017 Higher out-of-pocket expenses for tyrosine kinase-inhibitor therapy is associated with worse health-related quality-of-life in persons with chronic myeloid leukemia. CML, HRQoL, MCS, PCS, TKI, TKIs
59  2017 Performance of Sokal and Eutos Scores for Predicting Cytogenetic and Molecular Response in Newly Diagnosed Chronic Myeloid Leukemia-Chronic Phase Patients on Imatinib. CML, MMR
60  2017 Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia. MMR, TKI
61  2017 Ponatinib as a Valid Alternative Strategy in Patients with Blast Crisis-Chronic Myeloid Leukemia Not Eligible for Allogeneic Stem Cells Transplantation and/or Conventional Chemotherapy: Report of a Case. BC-CML
62  2017 The impact of medical insurance coverage and molecular monitoring frequency on outcomes in chronic myeloid leukemia: real-world evidence in China. CML, MMR
63  2017 The predictive value of early molecular response in chronic myeloid leukaemia patients treated with imatinib in a single real-world medical centre in a developing country. CML, EFS, MMR, OS
64  2017 Treatment and outcome of 2904 CML patients from the EUTOS population-based registry. CML, EUTOS, MMR, OS
65  2017 Trough concentration and ABCG2 polymorphism are better to predict imatinib response in chronic myeloid leukemia: a meta-analysis. CML, IM, MMR
66  2017 [A Case of Chronic Myelogenous Leukemia That Developed Fibrous Pericarditis Owing to Nilotinib Use]. CML
67  2017 [Analysis of Efficacy and Related Factors of Acquired Deep Molecular Response in Chronic Myeloid Leukemia Patients Treated with TKI]. CML, DMR, MCyR
68  2017 [Comparative study of cytogenetic response evaluated by conventional banding analysis and fluorescence in situ hybridization in chronic myeloid leukemia patients during tyrosine kinase inhibitor treatment]. CBA, CML, FISH, RQ-PCR, TKI
69  2017 [Comparison of generic and original imatinib in the treatment of newly diagnosed patients with chronic myelogenous leukemia in chronic phase: a multicenter retrospective clinical study]. CHR, CML-CP, EFS, MCyR, MR4.5, PFS
70  2017 [The clinical analysis of frontline nilotinib vs imatinib therapies for newly diagnosed chronic myeloid leukemia in chronic phase]. CML-CP, EFS, MMR, PFS
71  2016 Association between the concentration of imatinib in bone marrow mononuclear cells, mutation status of ABCB1 and therapeutic response in patients with chronic myelogenous leukemia. ABCB1, BMMCs, CML, hOCT1, IM, MMR, SNPs
72  2016 Clinical efficacy and safety of high-dose imatinib for chronic myeloid leukemia patients: An updated meta-analysis. CML, IM, OR
73  2016 Clinical Features and Treatment Outcomes of 51 Patients with Chronic Myeloid Leukemia Treated with a Tyrosine Kinase Inhibitor at a Single Institution from 2002 to 2014. BC, CML, MMR, MR4, OS, TKIs
74  2016 Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials. CML, CP, MMR, NG-TKIs, RR, TKIs
75  2016 Diagnosis and Monitoring of Chronic Myeloid Leukemia: Chiang Mai University Experience. CC, CML, CMR, FISH, MMR, Ph, RQ-PCR, TKI
76  2016 Fluorescent In Situ Hybridization Monitoring and Effect of Detected Early Responses in the Outcome of Patients With Chronic Phase Chronic Myeloid Leukemia: A Report From a Latin American Country. CBA, CML, CP, FISH
77  2016 Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia. CML, MF, TKIs
78  2016 Impact of Imatinib Adherence on the Cytogenetic Response in Pediatric Chronic Myeloid Leukemia - Chronic Phase. CML CP, CyR, PCyR
79  2016 [Clinical Efficacy of Second-generation Tyrosine Kinase Inhibitor in Treating Chronic Myeloid Leukemia]. CHR, CML, EFS, MCyR, MMR, OS, PFS, TKI
80  2016 [Dasatinib treatment based on BCR- ABL mutation detection in imatinib- resistant patients with chronic myeloid leukemia]. AP, BP, CHR, CML, CP, MMR, MR4.5, OS, PFS, TKI
81  2016 [Patient reported outcome of tyrosine kinase inhibitor related side effects and their impact on daily life in Chinese patients with chronic myeloid leukemia in the chronic phase]. CML, CMR, CP, TKI
82  2016 [The impact of Glivec related side effects on daily life in Chinese patients with chronic myeloid leukemia in the chronic phase]. CML, CMR, CP, TKI
83  2015 Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial. BELA, CML, CP, MMR
84  2015 Chronic myeloid leukemia with e14a3 BCR-ABL transcript: analysis of characteristics and prognostic significance. CML, FISH, Ph, qPCR
85  2015 Comparison of the utility and applicability of the Sokal, Hasford, and EUTOS scores in a population of Chinese patients with chronic-phase chronic myeloid leukemia undergoing imatinib therapy. CML, CP-CML, EFS, EUTOS, PFS
86  2015 Genetic variations of hOCT1 gene and CYP3A4/A5 genes and their association with imatinib response in Chronic Myeloid Leukemia. CML, hOCT1, MMR
87  2015 Immunological status of chronic myelogenous leukemia patients with complete cytogenetic response after treatment. CML, HHT, IM
88  2015 Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment. INTERIM, MMR
89  2015 Molecular Response in Patients with Chronic Myeloid Leukemia Treated with Imatinib - Single Centre Experience. CML, IM, MMR, MR, pts, TKI
90  2015 Successful Management of Pregnancy and Hepatic Toxicity in a CML Female Patient Treated with Nilotinib: a Case Report and a Review. CHR, MMR, TKI
91  2015 Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3months. MMR, MR1
92  2015 The impact of additional cytogenetic abnormalities at diagnosis and during therapy with tyrosine kinase inhibitors in Chronic Myeloid Leukaemia. ACAs, CML, Ph, TKI
93  2015 The occurrence of chronic lymphocytic leukemia after chronic phase of chronic myeloid leukemia: case report and literature review. CLL, CML, ELN, FISH, IM, LFS, MMR, TP53
94  2015 [Clinical Efficacy of Dasatinib, Nilotinib and Imatinib in Newly Diagnosed Patients with Chronic-Phase Chronic Myeloid Leukemia: A Three-year Retrospective Analysis]. CHR, CML, CP-CML, MMR, TKI
95  2015 [Clinical efficacy of switching to 2nd generation of tyrosine kinase inhibitor on CML patients at poor responses to imatinib]. ELN, MMR, TKI
96  2015 [Imatinib is effective in a 12-month-old boy with chronic myelogenous leukemia: case report and literature review]. CHR, CML
97  2015 [Imatinib mesylate for chronic myeloid leukemia: in patients with initial treatment versus those with Recombinant Human IFN-alpha2b treatment failure]. CML, CMR, IFN-alpha2b, IM, PCyR
98  2015 [Impact of age on the clinical response of patients with CML treated with imatinib]. CML, MMR, TKI
99  2014 Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib. CML-CP, ENESTcmr
100  2014 Definition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia. CHR, TKIs